Abstract:Background: Genetic mutations play a crucial role in the development and progression of myelodysplastic syndromes (MDS), impacting the immune microenvironment and influencing the choice of treatment regimen, as well as the efficacy and prognosis of patients. The objective of this study was to examine variations in hematological and immunological characteristics associated with common gene mutations in MDS patients and establish a foundation for the precise treatment of MDS. Methods: The hematological, immunological, and other clinical features of 71 recently diagnosed MDS patients from January 1, 2019, to July 31, 2023, were retrospectively analyzed. These patients were categorized based on their gene mutations, and the variances in hematological and immunological characteristics among distinct groups were compared. Results: Hematological variances were observed among different gene mutation groups. Specifically, platelet counts in the splicing factor 3B subunit 1 (SF3B1) mutation group were notably higher compared to the wild-type group (p = 0.009). Conversely, in the additional sex combs like 1 (ASXL1) mutation groups, monocyte ratios were significantly elevated in comparison to the wild-type group (p = 0.046), and in the ten-eleven translocation 2 (TET2) mutation group, lymphocyte ratios were significantly lower (p = 0.022). Additionally, the leukocyte (p = 0.005), neutrophil ratio (p = 0.002), and lymphocyte ratio (p = 0.001) were significantly higher in the Runt-related transcription factor 1 (RUNX1) mutation group. Regarding immunological distinctions, the Natural Killer (NK) cell ratio demonstrated a significant increase in the SF3B1 mutation group (p = 0.005). Moreover, the TET2 mutation group exhibited a significantly higher Interleukin-8 (IL-8) level (p = 0.017). In contrast, the U2 small nuclear RNA auxiliary factor 1 (U2AF1) group displayed significantly lower levels of IL-1β (p = 0.033), IL-10 (p = 0.033), and Tumour Necrosis Factor-α (TNF-α) (p = 0.009). Conclusion: Distinct variations exist in the immune microenvironment of MDS associated with different genetic mutations. Further studies are imperative to delve into the underlying mechanisms that drive these differences.

Evaluation of the Clinical Significance of Immunophenotyping in Myelodysplastic Syndrome.

[Karyotype Analysis of 283 Cases of Myelodysplastic Syndrome].

Analysis of the immunophenotype features of bone marrow cells of patients with myelodysplatic syndromes

Analysis of the Karyotype Abnormalities and Its Prognostic in 298 Patients with Myelodysplastic Syndrome

Immunophenotyping in Myelodysplastic Syndromes

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

[Evaluation of the Subsets of Lymphocytes and Their Activated Status in Patients with Myelodysplastic Syndrome].

The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes

Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes

Immunophenotyping of myelodysplastic syndromes by flow cytometry and its potential clinical application

Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes: FCMSS-assisted Diagnosis of MDS

Clinical Analysis of Myelodysplastic Syndrome

Analysis of Immunophenotypes in Patients with Leukemia and Myelodysplastic Syndrome by Direct Immunofluoresence

Immunophenotypic Features of Myelodysplastic Syndromes by CD45/SSC Gating and Flow Cytometry

Expression and Significance of CD123 and CD96 in Myelodysplastic Syndrome

[Research Advances in Value of Flow Cytometric Immunophenotyping in Diagnosis and Prognostic Evaluation of Myelodysplastic Syndrome].

Immune Dysregulation in Myelodysplastic Syndrome: Clinical Features, Pathogenesis and Therapeutic Strategies

Expression and significance of CD34, CD117 on bone marrow mononuclear cells of patients with myelodysplastic syndrome

Analyzing Differences in Hematological and Immunological Characteristics Related to Common Gene Mutations in Myelodysplastic Syndromes

Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome

An analysis of prognostic factors in 80 myelodysplastic syndrome